309 related articles for article (PubMed ID: 15234578)
21. Prolonged molecular remission in a newly diagnosed acute promyelocytic leukaemia with a severe cardiomyopathy using low-dose gemtuzumab ozogamicin and all-trans retinoic acid.
Martini V; Minotti C; Breccia M; De Angelis G; Buffolino S; Mariella M; Lo-Coco F; Avvisati G; Cimino G
Ann Hematol; 2007 Apr; 86(4):295-7. PubMed ID: 17136541
[No Abstract] [Full Text] [Related]
22. Long-term outcome of acute promyelocytic leukemia treated with all-
Abaza Y; Kantarjian H; Garcia-Manero G; Estey E; Borthakur G; Jabbour E; Faderl S; O'Brien S; Wierda W; Pierce S; Brandt M; McCue D; Luthra R; Patel K; Kornblau S; Kadia T; Daver N; DiNardo C; Jain N; Verstovsek S; Ferrajoli A; Andreeff M; Konopleva M; Estrov Z; Foudray M; McCue D; Cortes J; Ravandi F
Blood; 2017 Mar; 129(10):1275-1283. PubMed ID: 28003274
[TBL] [Abstract][Full Text] [Related]
23. Two patients with all-trans retinoic acid-resistant acute promyelocytic leukemia treated successfully with gemtuzumab ozogamicin as a single agent.
Takeshita A; Shinjo K; Naito K; Matsui H; Sahara N; Shigeno K; Suzumura T; Horii T; Shirai N; Maekawa M; Yada Y; Teshima H; Takeuchi J; Ohnishi K; Ohno R
Int J Hematol; 2005 Dec; 82(5):445-8. PubMed ID: 16533750
[TBL] [Abstract][Full Text] [Related]
24. Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia.
Song X; Hu X; Lü S; Gao L; Chen L; Yang J; Zhang W; Wang J
Eur J Haematol; 2014 Jul; 93(1):54-62. PubMed ID: 24592821
[TBL] [Abstract][Full Text] [Related]
25. Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care.
Iland HJ; Wei A; Seymour JF
Best Pract Res Clin Haematol; 2014 Mar; 27(1):39-52. PubMed ID: 24907016
[TBL] [Abstract][Full Text] [Related]
26. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.
Estey E; Garcia-Manero G; Ferrajoli A; Faderl S; Verstovsek S; Jones D; Kantarjian H
Blood; 2006 May; 107(9):3469-73. PubMed ID: 16373661
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells.
Takeshita A; Shinjo K; Naito K; Matsui H; Sahara N; Shigeno K; Horii T; Shirai N; Maekawa M; Ohnishi K; Naoe T; Ohno R
Leukemia; 2005 Aug; 19(8):1306-11. PubMed ID: 15920495
[TBL] [Abstract][Full Text] [Related]
28. [Therapies for newly diagnosed acute promyelocytic leukemia].
Yokoyama Y
Rinsho Ketsueki; 2020; 61(9):1166-1173. PubMed ID: 33162512
[TBL] [Abstract][Full Text] [Related]
29. Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide?
Tsimberidou AM; Kantarjian H; Keating MJ; Estey E
Leuk Lymphoma; 2006 Nov; 47(11):2282-8. PubMed ID: 17107899
[TBL] [Abstract][Full Text] [Related]
30. [Basic and clinical studies of the gene product-targeting therapy based on leukemogenesis--editorial].
Chen SJ; Chen LJ; Zhou GB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb; 13(1):1-8. PubMed ID: 15748426
[TBL] [Abstract][Full Text] [Related]
31. PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia.
Ohnishi K
Int J Clin Oncol; 2007 Oct; 12(5):313-7. PubMed ID: 17929112
[TBL] [Abstract][Full Text] [Related]
32. Insights into the All-trans-Retinoic Acid and Arsenic Trioxide Combination Treatment for Acute Promyelocytic Leukemia: A Meta-Analysis.
Ma H; Yang J
Acta Haematol; 2015; 134(2):101-8. PubMed ID: 25925330
[TBL] [Abstract][Full Text] [Related]
33. Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience.
Cheng Y; Zhang L; Wu J; Lu A; Wang B; Liu G
Eur J Haematol; 2013 Dec; 91(6):483-9. PubMed ID: 24033687
[TBL] [Abstract][Full Text] [Related]
34. CNS relapses of acute promyelocytic leukemia after all-trans retinoic acid.
Burry LD; Seki JT
Ann Pharmacother; 2002 Dec; 36(12):1900-6. PubMed ID: 12452754
[TBL] [Abstract][Full Text] [Related]
35. [Gemtuzumab ozogamicin successfully induced molecular remission in relapsed therapy-related acute promyelocytic leukemia].
Shimokawa T; Kojima Y
Rinsho Ketsueki; 2008 Apr; 49(4):270-2. PubMed ID: 18516871
[TBL] [Abstract][Full Text] [Related]
36. [Molecular remission induced by gemtuzumab ozogamicin in an elderly patient with relapsed acute promyelocytic leukemia].
Yago K; Aono M; Shimada H
Rinsho Ketsueki; 2010 Apr; 51(4):286-90. PubMed ID: 20467227
[TBL] [Abstract][Full Text] [Related]
37. Is There Still a Role for Low-Dose All-Transretinoic Acid in the Treatment of Acute Promyelocytic Leukemia in the Arsenic Trioxide Era?
Jaime-Pérez JC; González-Leal XJ; Pinzón-Uresti MA; Gómez-De León A; Cantú-Rodríguez OG; Gutiérrez-Aguirre H; Gómez-Almaguer D
Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):816-9. PubMed ID: 26500134
[TBL] [Abstract][Full Text] [Related]
38. Sustained molecular remission after arsenic trioxide and gemutuzumab ozogamicin in a pediatric patient with relapsed acute promyelocytic leukemia.
Inoue A; Kawakami C; Takitani K; Tamai H
Pediatr Hematol Oncol; 2012 Mar; 29(2):170-2. PubMed ID: 22292427
[No Abstract] [Full Text] [Related]
39. Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia.
Che-Pin Lin ; Huang MJ; Chang IY; Lin WY; Sheu YT
Leuk Lymphoma; 2000 Jun; 38(1-2):195-8. PubMed ID: 10811463
[TBL] [Abstract][Full Text] [Related]
40. Beneficial and adverse effects of molecularly targeted therapies for acute promyelocytic leukemia in central nervous system.
Nagai S; Takahashi T; Kurokawa M
CNS Neurol Disord Drug Targets; 2009 Nov; 8(5):387-92. PubMed ID: 19702568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
